ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.984,32
0,74%
S&P 500
5.970,84
-1,11%
Dow Jones
42.992,21
-0,77%
Euro vs US Dollar
1,04255
-0,03%
Bitcoin
93.555,12
0,02%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Mangoceuticals Inc (MGRX)

  7. Mangoceuticals Inc (MGRX) News

MGRX

Mangoceuticals (MGRX)

Mangoceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:MGRX
DatumZeitQuelleÜberschriftSymbolFirma
26/12/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MGRXMangoceuticals Inc
19/12/202423h33GlobeNewswire Inc.Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations PatentNASDAQ:MGRXMangoceuticals Inc
19/12/202423h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MGRXMangoceuticals Inc
06/12/202423h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MGRXMangoceuticals Inc
04/12/202413h00GlobeNewswire Inc.Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock SplitNASDAQ:MGRXMangoceuticals Inc
14/11/202422h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MGRXMangoceuticals Inc
12/11/202423h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MGRXMangoceuticals Inc
31/10/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MGRXMangoceuticals Inc
31/10/202413h00GlobeNewswire Inc.Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:MGRXMangoceuticals Inc
25/10/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MGRXMangoceuticals Inc
22/10/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MGRXMangoceuticals Inc
22/10/202414h00GlobeNewswire Inc.MangoRx Announces Formation of Strategy and Alternatives CommitteeNASDAQ:MGRXMangoceuticals Inc
21/10/202423h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MGRXMangoceuticals Inc
21/10/202423h10GlobeNewswire Inc.MangoRx Responds to and Refutes Recent Claims Made by Eli LillyNASDAQ:MGRXMangoceuticals Inc
11/10/202423h15GlobeNewswire Inc.MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLANNASDAQ:MGRXMangoceuticals Inc
03/10/202414h30GlobeNewswire Inc.MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss SolutionsNASDAQ:MGRXMangoceuticals Inc
01/10/202419h05AllPennyStocks.comHealthcare Shares Rise Following Product Availability AnnouncementNASDAQ:MGRXMangoceuticals Inc
01/10/202413h30GlobeNewswire Inc.MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss TreatmentNASDAQ:MGRXMangoceuticals Inc
15/08/202415h25GlobeNewswire Inc.MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024NASDAQ:MGRXMangoceuticals Inc
13/08/202422h00GlobeNewswire Inc.MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology PatentNASDAQ:MGRXMangoceuticals Inc
09/08/202414h15GlobeNewswire Inc.MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and TirzepatideNASDAQ:MGRXMangoceuticals Inc
24/07/202414h15GlobeNewswire Inc.MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention TechnologyNASDAQ:MGRXMangoceuticals Inc
18/07/202422h05GlobeNewswire Inc.Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-AccessNASDAQ:MGRXMangoceuticals Inc
16/07/202414h20GlobeNewswire Inc.MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via SurescriptsNASDAQ:MGRXMangoceuticals Inc
12/07/202419h30GlobeNewswire Inc.MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation DepartmentNASDAQ:MGRXMangoceuticals Inc
11/07/202414h15GlobeNewswire Inc.MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging MarketsNASDAQ:MGRXMangoceuticals Inc
18/06/202420h57Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MGRXMangoceuticals Inc
10/06/202419h28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MGRXMangoceuticals Inc
06/06/202414h30GlobeNewswire Inc.MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care TechnologyNASDAQ:MGRXMangoceuticals Inc
05/06/202423h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MGRXMangoceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MGRX

Kürzlich von Ihnen besucht

ASX
DRUG
BetaShares Capital
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten